Key facts
- Entactbio’s last known valuation is $75.9M.
- It has raised $126.7M; the latest was Later Stage VC ($40.3M) in May 2024.
- Notable investors include Qiming Venture Partners, Arkin Capital, Logos Capital, Revelation Partners, Surveyor Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Entactbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Entactbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Entactbio
Developer of a biotechnology research company designed to enhance the function of beneficial proteins. The company engages in natural cellular mechanisms by developing small-molecule drugs to create enhancement-targeting chimeric medicines, enabling patients to harness the ability of enzymes to regulate proteins.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2019
- Employees
- 33
- Website
- entactbio.com/
- Ownership
- Privately Held (backing)
Entactbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Entactbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Entactbio in its N-PORT filings yet. We sweep new filings monthly.